This study is the first to demonstrate that the presence of circulating N 3ÀHcyÀLys isopeptide (a degradation product of homocysteinylated proteins) in peripheral artery disease (PAD) patients with hyperhomocysteinemia during administration of folic acid that effectively reduces tHcy is associated with the PAD progression and an increased risk of cardiovascular events. Moreover, in PAD, circulating N 3ÀHcyÀLys isopeptide is associated with elevated asymmetric dimethylarginine (ADMA) levels, enhanced oxidative stress and impaired fibrinolysis reflected by increased plasminogen activator inhibitor-1 (PAI-1).
ADMA Cardiovascular disease Folic acid N 3ehomocysteinylelysine PAD Total homocysteine a b s t r a c t Objective: Folic acid (FA) administration can reduce plasma total homocysteine (tHcy); however, it fails to decrease cardiovascular events and progression of peripheral artery disease (PAD). N 3ehomocysteinylelysine isopeptide (N 3eHcyeLys) is formed during catabolism of homocysteinylated proteins. We sought to investigate factors that determine the presence of N 3eHcyeLys in PAD patients with hyperhomocysteinemia receiving FA.
Patients and methods: We studied 131 consecutive PAD patients with tHcy > 15 mmol l À1 taking FA 0.4 mg d À1 for 12 months. Serum N 3eHcyeLys was determined by high-performance liquid chromatography (HPLC). We also measured interleukin-6 (IL-6), plasminogen activator inhibitor-1 (PAI-1), asymmetric dimethylarginine (ADMA) and 8-iso-prostaglandin F 2a (8-iso-PGF 2a ). Results: FA administration resulted in a 70.5% decrease in tHcy (p < 0.0001). However, serum N 3eHcyeLys was detectable in 28 (21.4%) patients on FA who were more frequently current smokers and survivors of ischaemic stroke (p < 0.001). They had higher tHcy by 46.0%, PAI-1 by 51.7%, 8-iso-PGF 2a by 59.1% and ADMA by 26 .4% (all, p < 0.0001). The presence of N 3eHcyeLys was associated with lower ankle-brachial index (ABI) values (p < 0.001) and higher prevalence of cardiovascular events (p < 0.001) following therapy. Conclusion: The presence of N 3eHcyeLys in one-fifth of hyperhomocysteinemic individuals with PAD despite FA treatment is associated with progression of PAD and with increased ADMA formation, oxidative stress and hypofibrinolysis.
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Peripheral artery disease (PAD) results in narrowing of largeand medium-sized arteries in lower extremities, and is associated with an increased risk of myocardial infarction (MI) and stroke. 1 Estimated prevalence of PAD, defined as an ankle-brachial index (ABI) of 0.90, ranges from 2.5% in the age group 50e59 years to 14.5% in subjects >70 years. 2 Risk factors for PAD are similar to those of coronary artery disease (CAD), and CAD is present in 20e50% of the PAD patients. 3 Potential markers of PAD progression include C-reactive protein (CRP), proinflammatory cytokines, fibrinogen, D-dimer, tissue plasminogen activator, plasminogen activator inhibitor-1 (PAI-1), together with 8-iso-prostaglandin F 2a (8-iso-PGF 2a ), asymmetric dimethylarginine (ADMA), and total homocysteine (tHcy). 4e6 Elevated plasma tHcy is associated with an increased risk of vascular events, but trials failed to show clinical benefits from Hcylowering therapy in cardiovascular patients. 7 Homocysteine can be metabolised to Hcyethiolactone, a reactive thioester that causes protein N-homocysteinylation, that may impair or alter protein function. 8, 9 N 3ehomocysteinyleLysine (N 3eHcyeLys), an isopeptide generated during proteolytic degradation of N 3eHcyeproteins, has recently been identified. 10 N 3eHcyeLys is elevated in acute MI. 11 Circulating concentrations of this isopeptide are related to plasma ADMA, a nitric oxide (NO) synthase inhibitor, which is formed by methylation of protein Larginine residues. 11, 12 ADMA has been reported to be an independent risk marker for all-cause and cardiovascular death in PAD patients. 13 A large meta-analysis showed that patients with PAD had higher Hcy levels than those observed in controls without PAD. 14 Folic acid (FA) supplementation reduces plasma tHcy and improves ABI, but it does not reduce cardiovascular risk among subjects with prior history of vascular disease. 15, 16 We tested the hypothesis that N 3eHcyeLys isopeptide is present in a subset of hyperhomocysteinemic individuals with PAD despite FA treatment and that this phenomenon is associated with progression of PAD. We also sought to determine factors that are linked with the presence of measurable N 3eHcyeLys levels.
Patients and Methods

Patients
Consecutive patients with PAD, defined as an ABI 0.9 measured using established methods and hyperhomocysteinemia, defined as plasma Hcy concentration !15 mmol l À1 were recruited to the study (n ¼ 131). All eligible patients denied taking any vitamin preparations within the 6 months preceding the enrolment. The exclusion criteria were: a history of venous thromboembolism, recent (<6 months) arterial thrombotic event, angioplasty or surgery, active cancer, liver cirrhosis, renal failure (serum creatinine >177 mmol l À1 ), any acute illness, current anticoagulant therapy. CAD was defined as a history of MI, coronary revascularisation, or hospitalisation for angina symptoms. Diabetes and stroke were diagnosed according to the World Health Organisation (WHO) criteria. Hypercholesterolaemia was defined as a low-density lipoprotein (LDL) cholesterol >3.0 mmol l À1 or total cholesterol >5 mmol l À1 or treatment with cholesterol-lowering medication. 17 An individual was classified as having arterial hypertension if he/she met one of the following criteria: (1) previous history of hypertension; (2) current antihypertensive treatment; (3) systolic or diastolic pressure !140 mmHg or !90 mmHg, respectively, on at least two different occasions. Heart failure was diagnosed in subjects with decreased left ventricular ejection fraction <50% on echocardiography. Chronic obstructive pulmonary disease was defined as forced expiratory volume in 1 s divided by forced vital capacity below 70% of normal values.
All recruited patients received the treatment with FA 0.4 mg once daily. They were asked not to change their diet and abstain from vitamin supplements throughout the study period. All subjects were followed for 1 year. None of the patients were lost to follow-up. Four patients declared quitting smoking. Clinical and laboratory parameters were collected after one year of FA treatment. We defined the progression of PAD as decrease in ABI of >0.15 during the treatment. Other clinical end points were a new MI or stroke during follow-up.
The study was approved by the Jagiellonian University Ethical Committee, and all patients provided written informed consent.
Laboratory investigations
Prior to the onset of FA administration and following 1 year of the therapy, blood was drawn from an antecubital vein with minimal stasis after an overnight fast between 8 and 10 AM. Platelet count, glucose, lipid profile and creatinine were assayed by routine laboratory techniques. Fibrinogen was determined using the Clauss method and CRP by the latex nephelometry (Dade Behring, Marburg, Germany).
tHcy, cysteine and gluthatione (GSH) in plasma were assayed by high-performance liquid chromatography (HPLC) as described. 18 Serum folate levels were measured using a commercial kit (Abbott Laboratories). Commercially available immunoenzymatic assays were used to determine PAI-1 (American Diagnostica, Greenwich, CT, USA), 8-iso-PGF 2a (Cayman Chemicals, Ann Arbor, MI, USA) and interleukin-6 (IL-6) (R&D Systems, Abingdon, UK). All parameters were measured in duplicate by an investigator blinded to the sample origin. Plasma ADMA was assayed by HPLC as described. 19 Intra-assay and inter-assay coefficients of variation were <8%.
After 12 months of FA administration, serum N 3eHcyeLys levels were assayed using the method by G1owacki et al. 10, 20 The limit of quantification is 0.1 mmol l À1 . Intra-assay and inter-assay coefficients of variation were 4.3 and 7.5%, respectively.
Statistical analysis
Continuous variables were presented as mean AE standard deviation or median and quartiles as appropriate. Categorical variables were presented as percentages. The ShapiroeWilk test was used to assess the normality of continuous variables. To examine the differences between two independent groups Student's t-test (for normally distributed variables) or ManneWhithey test (for non-normally distributed variables) were used. The Fisher exact test was employed when both variables were categorical. To assess linear dependence between variables the Pearson correlation coefficient (Pearson's r) for normally distributed variables or Spearman's rank correlation coefficient (Spearman's rho) for non-normally distributed variables were calculated. Relationships between measurable N 3eHcyeLys and other variables adjusted for potential confounders (age, gender, body mass index (BMI), current smoking, positive stroke history and pretreatment folate concentrations) were analysed by multiple linear regressions. The independent predictors of N 3eHcyeLys were identified using a stepwise multivariate Firth's logistic regression. Firth's logistic regression was used to obtain odds ratios with 95% confidence interval (CI) adjusted for confounding factors. Statistical analysis was performed with STATISTICA 9.0 (StatSoft, Tulsa, Oklahoma, USA). Two sided p-values <0.05 were considered statistically significant.
Abbreviations
Results
A total of 131 PAD patients, mostly hypercholesterolemic and hypertensive subjects, with a median ABI of 0.72 (Table 1) and tHcy above 15 mmol l À1 (interquartile range, 16.9e20.2 mmol l À1 ) ( Table 2) were studied. Treatment with FA resulted in 70.5% decrease in tHcy (p < 0.0001). As expected, folate concentrations increased from a median of 13.9 nmol l À1 (10.5e15.9) to 40.8 nmol l À1 (37.2e47.0) after the treatment. Detectable serum N 3eHcyeLys concentrations (median 0.08 mmol l À1 (0.05e0.13)) were present in 28 (21.4%) patients, who had 46% higher posttreatment tHcy (p < 0.0001) as compared with the subjects with undetectable N 3eHcyeLys ( Table 3) . Comparison of patients with detectable N 3eHcyeLys following FA administration with the remaining subjects (Table 1) showed that the groups differed with regard to history of prior ischaemic stroke and current smoking.
Routine laboratory variables were similar in both groups except for slightly lower triglycerides and higher fibrinogen in patients with detectable N 3eHcyeLys ( Table 2 ). Circulating PAI-1 antigen, and 8-iso-PGF 2a were higher in patients with detectable N 3eHcyeLys (Table 2 ). This group had 26.4% higher plasma ADMA (Table 3) .
A 1-year follow-up showed that patients with detectable N 3eHcyeLys, compared to individuals with non-measurable N 3eHcyeLys concentrations, more often experienced new MI (12 (43%) vs. eight (8%); p < 0.0001) and stroke (five (18%) vs. 0 (0%); Table 1 Baseline characteristics of PAD patients classified into two groups based on N 3eHcyeLys levels after FA treatment.
Variable
The p < 0.001) during the treatment. Of note, we observed lower ABI values in subjects with detectable N 3eHcyeLys after FA treatment (p < 0.001). In this group, we also observed a decline in ABI values (0.76 (0.67e0.81) to 0.62 (0.55e0.71), p < 0.0001) that was absent in the remaining patients. PAD progression was observed in four (14%) individuals with measurable N 3eHcyeLys and there was no PAD progression observed in the remaining group. Combined end point of MI, stroke and PAD progression was observed in 75% of patients with detectable N 3eHcyeLys, as opposed to only 8% in the remaining individuals. We observed positive correlations between post-treatment N 3eHcyeLys concentrations and plasma ADMA ( Fig. 1A) , glutathione (GSH) (r ¼ 0.18; p ¼ 0.035) and tHcy (r ¼ 0.44; p < 0.0001) after FA administration. There were also positive correlations between N 3eHcyeLys and baseline PAI-1 (Fig. 1B) , 8iso-PGF 2a (Fig. 1C) and fibrinogen (r ¼ 0.20; p ¼ 0.019). There was an inverse correlation between post-treatment N 3eHcyeLys and ABI after 1 year of follow-up ( Fig. 1D ). Multivariate analysis showed that baseline plasma PAI-1 and 8iso-PGF 2a concentrations were the independent predictors of presence of measurable N 3eHcyeLys in PAD patients treated with FA (OR per 1 unit increase (95% CI): 1.24 (1.12e1.52), p < 0.001 and OR per 1 unit increase (95% CI): 1.03 (1.02e1.07), p < 0.001, Table 3 Laboratory and clinical variables in PAD patients after one-year treatment with folic acid.
The whole group n ¼ 131 
Discussion
This study demonstrates that the presence of circulating N 3eHcyeLys isopeptide in PAD patients with hyperhomocysteinemia during administration of FA that effectively reduces tHcy is associated with the PAD progression and an increased risk of cardiovascular events. Moreover, we showed that in PAD, circulating N 3eHcyeLys isopeptide is associated with elevated ADMA levels, enhanced oxidative stress and impaired fibrinolysis reflected by increased PAI-1. Our study might help to understand the failure of studies to yield clinical benefits despite lowering of tHcy. 21, 22 Most likely, the presence of circulating N 3eHcyeLys is largely driven by increased generation of Hcyproteins in PAD patients with hyperhomocysteinemia.
Our findings suggest that the presence of N 3eHcyeLys predisposes to cerebrovascular events or it is a marker of previous cerebral ischaemia. Detectable N 3eHcyeLys is frequent in current smokers. Smoking is associated with hyperhomocysteinemia and oxidative stress. 23, 24 Moreover, our study provides additional evidence for the association between Hcy and ADMA metabolism in atherosclerosis.
Impaired fibrinolysis attributed to fibrinogen modification by Hcy is supported by our finding that in PAD patients with N 3eHcyeLys in blood, plasma PAI-1, typically increased in PAD patients, positively correlated with N 3eHcyeLys. 25, 26 The presence of detectable N 3eHcyeLys was also associated with oxidative stress, which suggests that N 3eHcyeLys is linked with processes implicated in cardiovascular disease, including platelet activation. 27 Interestingly, the use of ACEI was shown to be an independent predictor of the absence of measurable N 3eHcyeLys in our study. ACEIs can lower plasma ADMA and tHcy. 28,29 It has been demonstrated that ramipril may prevent cardiovascular events in PAD patients. 30 This observation merits further investigation.
Our study has several limitations. The number of study participants was limited. We determined N 3eHcyeLys solely following FA administration, therefore we cannot assess the changes in this parameter during Hcy-lowering therapy. Autoimmune response to homocysteinylated proteins was not determined. 31 In conclusion, in patients with PAD, N 3eHcyeLys measurable in peripheral blood is associated with cardiovascular events and PAD progression. Larger studies are needed to assess clinical relevance of the current findings. 
